Head and Neck Cancer
- Larynx, Lip, Oral Cavity and PharynxPhase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)Principal Investigator: Melissa Young
- Corpus Uteri, Larynx, Lung, Soft Tissue, Unknown SitesA Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid TumorsPrincipal Investigator: Alessandro Santin
- Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Thyroid, Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Principal Investigator: Barbara Burtness
- Larynx, Lip, Oral Cavity and PharynxA Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell CarcinomaPrincipal Investigator: Barbara Burtness
- Larynx, Soft Tissue, Unknown SitesA Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPrincipal Investigator: Aarti Bhatia